0000000000729500
AUTHOR
Pauline Pistre
showing 4 related works from this author
Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department
2020
Objectives To evaluate clinical and financial impact of pharmacist interventions in an ambulatory adult hematology–oncology department. Methods All cancer patients receiving a first injectable immuno- and/or chemotherapy regimen were included in this prospective study over a one-year period. The clinical impact of pharmacist interventions made by two clinical pharmacists was rated using the Clinical Economic and Organizational tool. Financial impact was calculated through cost savings and cost avoidance. Main results: Five hundred and fifty-eight patients were included. A total of 1970 pharmacist interventions were performed corresponding to a mean number of 3.5 pharmacist interventions/pat…
Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.
2020
International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…
Safety of ninety-minute daratumumab infusion.
2020
Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours. The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion. Patients and methods All patients who had received two or more doses of daratumumab in monotherapy or in combination with standard infusion rates were included. We excluded patients enrolled in clinical trials. For the rapid infu…
sj-pdf-1-opp-10.1177_1078155220915763 - Supplemental material for Clinical and economic impact of pharmacist interventions in an ambulatory hematolog…
2020
Supplemental material, sj-pdf-1-opp-10.1177_1078155220915763 for Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department by Jonathan de Grégori, Pauline Pistre, Meredith Boutet, Laura Porcher, Madeline Devaux, Corinne Pernot, Marie L Chrétien, Cédric Rossi, Sylvain Manfredi, Sophie Dalac, Pauline Gueneau and Mathieu Boulin in Journal of Oncology Pharmacy Practice